

Specialty Medication Prior Authorization Cover Sheet

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to www.uhcprovider.com for medication fax request forms.)

Patient Information

Patient's Name: _____

Insurance ID: _____ Date of Birth: _____ Height: _____ Weight: _____

Address: _____ Apartment #: _____

City: _____ State: _____ Zip Code: _____

Phone Number: _____ Alternate Phone: _____ Sex: Male Female

Provider Information

Provider's Name: _____ Provider ID Number: _____

Address: _____ City: _____ State: _____ Zip Code: _____

Suite Number: _____ Building Number: _____

Phone Number: _____ Fax number: _____

Provider's Specialty: _____

Medication Information

Medication: _____ Quantity: _____ ICD10 Code: _____

Directions: _____ Diagnosis: _____ Refills: _____

Physician Signature:** _____ Initial here if DAW: _____

*Physician Signature**:* By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.

Medication Instructions

Has the patient been instructed on how to **Self-Administer**? Yes No

Is this medication a **New Start**? Yes No

If continuation please provide the following: Initiation Date: / / Date of Last Dose: / /

Is there documentation of positive clinical response to current therapy? Yes No

****Please attach any pertinent clinical information that would pertain to support stated diagnosis. Additional clinical information may be needed depending on your patients plan, including medication(s) previously tried and failed.**

Delivery Instructions

Note: Delivery coordination requires a "Physician Signature" above and complete "Provider Information" and "Patient Information"

Note: All necessary ancillary supplies are provided free of charge to the patient at the time of delivery

Ship to: Physician's Office Patient's Address Date medication is needed: / /

Medication Administered: Home Health Self-Administered LTC Physician's Office

Please complete this entire form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826**.

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:

Primary Insurance Information:

Is the requested medication New or Continuation of Therapy? If continuation, list start date: _____

Is this patient currently hospitalized? Yes No If recently discharged, list discharge date: _____

Section B - Provider Information

First Name:	Last Name:	M.D./D.O.	
Address:	City:	State:	ZIP code:
Phone:	Fax:	NPI #:	Specialty:

Office Contact Name / Fax attention to:

Section C - Medical Information

Medication:	Strength:
Directions for use:	Quantity:
Diagnosis (Please be specific & provide as much information as possible):	ICD-10 CODE:

Is this member pregnant? Yes No If yes, what is this member's due date? _____

Section D – Previous Medication Trials

Medications	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

**Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs:
Please refer to the patient's PDL at www.uhcprovider.com for a list of preferred alternatives**

Member First name:	Member Last name:	Member DOB:
---------------------------	--------------------------	--------------------

Clinical and Drug Specific Information

ALL REQUESTS

<input type="checkbox"/> Yes <input type="checkbox"/> No	<p>Does the patient have one of the following diagnoses? <i>(If yes, check which applies)</i></p> <table style="width:100%; border:none;"> <tr> <td style="width:50%; border:none;"><input type="checkbox"/> AIDS-related B-cell Lymphoma</td> <td style="width:50%; border:none;"><input type="checkbox"/> Chronic Graft Versus Host Disease</td> </tr> <tr> <td style="border:none;"><input type="checkbox"/> Chronic Lymphocytic Leukemia (CLL)</td> <td style="border:none;"><input type="checkbox"/> Diffuse large B-cell Lymphoma</td> </tr> <tr> <td style="border:none;"><input type="checkbox"/> Follicular Lymphoma (grade 1-2)</td> <td style="border:none;"><input type="checkbox"/> Gastric MALT Lymphoma</td> </tr> <tr> <td style="border:none;"><input type="checkbox"/> Hairy Cell Leukemia (HCL)</td> <td style="border:none;"><input type="checkbox"/> Mantle Cell Lymphoma (MCL)</td> </tr> <tr> <td style="border:none;"><input type="checkbox"/> Marginal Zone Lymphoma (MZL)</td> <td style="border:none;"><input type="checkbox"/> Nongastric MALT Lymphoma</td> </tr> <tr> <td style="border:none;"><input type="checkbox"/> Non-Hodgkin's Lymphoma (NHL)</td> <td style="border:none;"><input type="checkbox"/> Post-transplant Lymphoproliferative Disorders</td> </tr> <tr> <td style="border:none;"><input type="checkbox"/> Primary CNS Lymphoma</td> <td style="border:none;"><input type="checkbox"/> Small Lymphocytic Lymphoma (SLL)</td> </tr> <tr> <td style="border:none;"><input type="checkbox"/> Waldenström's Macroglobulinemia/ Lymphoplasmacytic Lymphoma</td> <td></td> </tr> </table>	<input type="checkbox"/> AIDS-related B-cell Lymphoma	<input type="checkbox"/> Chronic Graft Versus Host Disease	<input type="checkbox"/> Chronic Lymphocytic Leukemia (CLL)	<input type="checkbox"/> Diffuse large B-cell Lymphoma	<input type="checkbox"/> Follicular Lymphoma (grade 1-2)	<input type="checkbox"/> Gastric MALT Lymphoma	<input type="checkbox"/> Hairy Cell Leukemia (HCL)	<input type="checkbox"/> Mantle Cell Lymphoma (MCL)	<input type="checkbox"/> Marginal Zone Lymphoma (MZL)	<input type="checkbox"/> Nongastric MALT Lymphoma	<input type="checkbox"/> Non-Hodgkin's Lymphoma (NHL)	<input type="checkbox"/> Post-transplant Lymphoproliferative Disorders	<input type="checkbox"/> Primary CNS Lymphoma	<input type="checkbox"/> Small Lymphocytic Lymphoma (SLL)	<input type="checkbox"/> Waldenström's Macroglobulinemia/ Lymphoplasmacytic Lymphoma	
<input type="checkbox"/> AIDS-related B-cell Lymphoma	<input type="checkbox"/> Chronic Graft Versus Host Disease																
<input type="checkbox"/> Chronic Lymphocytic Leukemia (CLL)	<input type="checkbox"/> Diffuse large B-cell Lymphoma																
<input type="checkbox"/> Follicular Lymphoma (grade 1-2)	<input type="checkbox"/> Gastric MALT Lymphoma																
<input type="checkbox"/> Hairy Cell Leukemia (HCL)	<input type="checkbox"/> Mantle Cell Lymphoma (MCL)																
<input type="checkbox"/> Marginal Zone Lymphoma (MZL)	<input type="checkbox"/> Nongastric MALT Lymphoma																
<input type="checkbox"/> Non-Hodgkin's Lymphoma (NHL)	<input type="checkbox"/> Post-transplant Lymphoproliferative Disorders																
<input type="checkbox"/> Primary CNS Lymphoma	<input type="checkbox"/> Small Lymphocytic Lymphoma (SLL)																
<input type="checkbox"/> Waldenström's Macroglobulinemia/ Lymphoplasmacytic Lymphoma																	

<input type="checkbox"/> Yes <input type="checkbox"/> No	<p>Is the medication being requested for a use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium?</p> <p><i>If yes, list supported use:</i></p>
--	---

NON-HODGKIN'S LYMPHOMA

<input type="checkbox"/> Yes <input type="checkbox"/> No	<p>Does either of the following apply?</p> <ul style="list-style-type: none"> - Patient has received at least one prior therapy for MCL [e.g., Rituxan (rituximab)] - Imbruvica will be used in pre-treatment therapy in combination with Rituxan (rituximab) to limit the number of cycles with RHyperCVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen
--	--

<input type="checkbox"/> Yes <input type="checkbox"/> No	Will Imbruvica be used as second-line or a subsequent therapy?
--	---

MARGINAL ZONE LYMPHOMA (MZL)

<input type="checkbox"/> Yes <input type="checkbox"/> No	<p>Does the patient have either of the following diagnoses?</p> <ul style="list-style-type: none"> - Nodal or splenic marginal zone lymphoma (MZL) - Histological transformation to diffuse large B-cell lymphoma
--	--

<input type="checkbox"/> Yes <input type="checkbox"/> No	Has the patient received any prior anti-CD20-based therapy for MZL [e.g., Rituxan (rituximab), Zevalin (ibrutumomab), Gazyva (obinutuzumab), etc.]? <i>(If yes, complete Section D above)</i>
--	--

CHRONIC GRAFT VERSUS HOS DISEASE

<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient have a history of failure of any systemic therapy [e.g., corticosteroids, mycophenolate, etc.]? <i>(If yes, complete Section D above)</i>
--	---

PRIMARY CNS LYMPHOMA

<input type="checkbox"/> Yes <input type="checkbox"/> No	Will Imbruvica be used as second-line or a subsequent therapy (e.g., radiation or chemotherapy)?
--	---

CONTINUATION OF THERAPY

<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient show evidence of progressive disease while on Imbruvica therapy?
--	--

<input type="checkbox"/> Yes <input type="checkbox"/> No	Does the patient show evidence of positive clinical response while on Imbruvica therapy?
--	---

Physician Signature: _____ **Date:** _____

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.